newsfilter
← Latest News
GlobeNewswire·

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived